Patent Assignment
Reel/Frame 050166/0001
Assignment of Assignor's Interest
Recorded: 2019-08-26
Pages: 222
Assignor
SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Executed: 2019-08-06
Assignee
PRECISION IBD, INC.
3525 DEL MAR HEIGHTS RD. #342, SAN DIEGO, CALIFORNIA, 92130
Covered Properties
(199)
Methods of Diagnosing Liver Fibrosis
PCT:
PCT/US2003/006038 ↗
Methods of Quantifying Methotrexate Metabolites
PCT:
PCT/US2003/027313 ↗
Method for Direct Detection of Individual Methotrexate Metabolities
PCT:
PCT/US2004/006312 ↗
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
PCT:
PCT/US2004/027851 ↗
Methods of Diagnosing Tissue Fibrosis
PCT:
PCT/US2004/035766 ↗
Methods of Diagnosing Inflammatory Bowel Disease
PCT:
PCT/US2005/016965 ↗
Methods for Predicting Methotrexate Polyglutamate Levels Using Pharmacogenetics
PCT:
PCT/US2005/020957 ↗
Method for Optimizing Thiopurine Efficacy and Toxicity Using Mass Spectrometry
PCT:
PCT/US2005/041272 ↗
Methods of Predicting Methotrexate Efficacy and Toxicity
PCT:
PCT/US2006/016246 ↗
Methods of Diagnosing Inflammatory Bowel Disease
PCT:
PCT/US2006/046136 ↗
Crohn Disease Susceptibility Gene
PCT:
PCT/US2007/074481 ↗
Methods for Diagnosing Irritable Bowel Syndrome
PCT:
PCT/US2007/075976 ↗
Methods and Agents for Evaluating Inflammatory Bowel Disease, and Targets for Treatment
PCT:
PCT/US2008/058281 ↗
Addressable Antibody Arrays and Methods of Use
PCT:
PCT/US2009/037566 ↗
Methods for Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
PCT:
PCT/US2009/063924 ↗
Citrullinated Peptides for Diagnosing and Prognosing Rheumatoid Arthritis
PCT:
PCT/US2010/028946 ↗
Inflammatory Bowel Disease Prognostics
PCT:
PCT/US2010/030934 ↗
Methods for Diagnosing Irritable Bowel Syndrome
PCT:
PCT/US2010/039866 ↗
Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
PCT:
PCT/US2010/054125 ↗
Methods for Diagnosing Irritable Bowel Syndrome
PCT:
PCT/US2010/054810 ↗
Methods for Predicting Post-Surgery Risk Associated with Ileal Pouch-Anal Anastomosis
PCT:
PCT/US2010/056271 ↗
Novel Genomic Biomarkers for Irritable Bowel Syndrome Diagnosis
PCT:
PCT/US2010/058099 ↗
Methods for Improving Inflammatory Bowel Disease Diagnosis
PCT:
PCT/US2011/039174 ↗
Methods for Determining Anti-Drug Antibody Isotypes
PCT:
PCT/US2011/056777 ↗
HER2DELTA16 Peptides
PCT:
PCT/US2011/062954 ↗
Performance of a Biomarker Panel for Irritable Bowel Syndrome
PCT:
PCT/US2012/038197 ↗
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia or Cancer
PCT:
PCT/US2012/042533 ↗
Assays for Detecting Neutralizing Autoantibodies to Biologic Therapy
PCT:
PCT/US2012/045794 ↗
Compositions and Methods for Detecting Allelic Variants
PCT:
PCT/US2012/051442 ↗
Methods for Determining Combination Therapy with Il-2 for the Treatment of Cancer
PCT:
PCT/US2012/056753 ↗
Methods for Improving Inflammatory Bowel Disease Diagnosis
PCT:
PCT/US2012/061202 ↗
Inflammatory Bowel Disease First Step Assay System
Patent:
6,218,129 →
Application:
09/079,435 →
Method of Determining Thiopurine Methyltransferase Activity
Methods of Diagnosing Liver Fibrosis
Methods of Quantifying Methotrexate Metabolites
Methods for Direct Detection of Individual Methotrexate Metabolites
Method of Determining Thiopurine Methyltransferase Acitivity
Methods of diagnosing liver fibrosis
Application:
10/504,544 →
Publication:
US 2006/0084057
Methods of Diagnosing Tissue Fibrosis
Methods of Diagnosing Inflammatory Bowel Disease
Method for optimizing thiopurine efficacy and toxicity using mass spectrometry
Application:
11/274,104 →
Publication:
US 2006/0216726
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
11/380,171 →
Publication:
US 2006/0286571
Methods of Diagnosing Inflammatory Bowel Disease
Method and System for Assisting in Diagnosing Irritable Bowel Syndrome
Patent:
7,943,328 →
Application:
11/679,149 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
11/838,810 →
Publication:
US 2008/0085524
Methods for Diagnosing Irritable Bowel Syndrome
Methods of Diagnosing Inflammatory Bowel Disease
Application:
11/841,699 →
Publication:
US 2008/0182280
Methods for Diagnosing Irritable Bowel Syndrome
Patent:
8,685,741 →
Application:
12/043,082 →
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application:
12/191,286 →
Publication:
US 2009/0197266
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application:
12/191,287 →
Publication:
US 2009/0197267
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application:
12/191,290 →
Publication:
US 2009/0197268
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
12/194,501 →
Publication:
US 2010/0203507
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
12/194,503 →
Publication:
US 2010/0203508
Addressable Antibody Arrays and Methods of Use
Application:
12/209,863 →
Publication:
US 2009/0081711
Methods for Diagnosing Irritable Bowel Syndrome
Application:
12/253,177 →
Publication:
US 2010/0094560
Crohn Disease Susceptibility Gene
Application:
12/309,635 →
Publication:
US 2010/0099083
Methods to Predict Risk for Celiac Disease by Detecting Anti-Flagellin Antibody Levels
Patent:
8,409,819 →
Application:
12/392,997 →
Methods and Agents for Evaluating Inflammatory Bowel Disease, and Targets for Treatment
Application:
12/450,478 →
Publication:
US 2010/0167285
Methods of Quantifying Methotrexate Metabolites
Application:
12/484,148 →
Publication:
US 2010/0159493
Addressable Antibody Arrays and Methods of Use
Methods for Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
Application:
12/615,983 →
Publication:
US 2010/0129838
Methods of Diagnosing Tissue Fibrosis
Application:
12/695,126 →
Publication:
US 2010/0317022
Methods for Predicting Methotrexate Polyglutamate Levels Using Pharmacogenetics
Application:
12/698,966 →
Publication:
US 2010/0203539
A Method for Determining the Risk of Crohn's Disease-Related Complications
Methods for Diagnosing Irritable Bowel Syndrome
Methods of Diagnosing Inflammatory Bowel Disease
Methods of Quantifying Methotrexate Metabolites
Application:
13/158,082 →
Publication:
US 2011/0262948
Assays and Methods for the Detection of Crohn's Disease
Patent:
8,445,215 →
Application:
13/190,369 →
Citrullinated Peptides for Diagnosing and Prognosing Rheumatoid Arthritis
Inflammatory Bowel Disease Prognostics
Application:
13/283,511 →
Publication:
US 2012/0171672
Methods for Diagnosing Irritable Bowel Syndrome
Methods for Diagnosing Irritable Bowel Syndrome
Application:
13/441,658 →
Publication:
US 2012/0315630
Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Novel Genomic Biomarkers for Irritable Bowel Syndrome Diagnosis
Application:
13/479,127 →
Publication:
US 2013/0005596
Addressable Antibody Arrays and Methods of Use
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
13/686,861 →
Publication:
US 2013/0203053
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
13/709,558 →
Publication:
US 2013/0143215
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Application:
13/750,282 →
Publication:
US 2013/0131072
Mobility Shift Assays for Detecting Anti-Tnf Alpha Drugs and Autoantibodies Thereto
Application:
13/797,815 →
Publication:
US 2014/0051184
Assay for Detecting Neutralizing Autoantibodies to Biologic Therapy
Application:
13/802,117 →
Publication:
US 2013/0266963
Methods for Improving Inflammatory Bowel Disease Diagnosis
Mobility Shift Assays for Detecting Anti-Tnf Alpha Drugs and Autoantibodies
Application:
13/859,664 →
Publication:
US 2013/0295685
Methods for Determining Anti-Drug Antibody Isotypes
Methods for Diagnosing Irritable Bowel Syndrome
Application:
13/891,128 →
Publication:
US 2014/0051594
HER2DELTA16 Peptides
Citrullinated Peptides for Diagnosing and Prognosing Rheumatoid Arthritis
Application:
13/952,499 →
Publication:
US 2014/0170683
Assays for Detecting Autoantibodies to Anti-Tnfalpha Drugs
Application:
13/961,841 →
Publication:
US 2014/0045276
Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Performance of a Biomarker Panel for Irritable Bowel Syndrome
Application:
14/071,581 →
Publication:
US 2014/0141990
Methods of Disease Activity Profiling for Personalized Therapy Management
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia or Cancer
Application:
14/102,432 →
Publication:
US 2014/0179549
Assays for Detecting Neutralizing Autoantibodies to Biologic Therapy
Compositions and Methods for Detecting Allelic Variants
Methods for Diagnosing Irritable Bowel Syndrome
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
14/229,715 →
Publication:
US 2015/0072879
Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Antibodies to Microbiome, Stress Factors and Mast Cell Markers as Diagnostic Markers for Ibs
Methods for Predicting and Monitoring Mucosal Healing
Application:
14/678,455 →
Publication:
US 2015/0355195
HER2DELTA16 Peptides
Pathway Specific Assays for Predicting Irritable Bowel Syndrome Diagnosis
Pathway Specific Markers for Diagnosing Irritable Bowel Syndrome
Methods for Predicting Post-Operative Recurrence of Crohn's Disease
Signaling Pathways in Tissues from Inflammatory Bowel Disease Patients
Application:
15/171,970 →
Publication:
US 2016/0356790
Biomarker Panel for Assessment of Mucosal Healing
Assays for Detecting Neutralizing Autoantibodies to Biologic Therapy
Assays for the Detection of Anti-TNF Drugs and Autoantibodies
HER2DELTA16 Peptides
Methods for Predicting Clinical Outcomes in Subjects Afflicted with Ulcerative Colitis
Application:
15/484,878 →
Publication:
US 2017/0219605
Methods for Prediction of Anti-Tnf Alpha Drug Levels and Autoantibody Formation
Antibodies Against Serotonin, Tryptophan and Kynurenine Metabolites and Uses Thereof
Application:
15/587,739 →
Publication:
US 2017/0240652
Methods for Establishing a Vedolizumab Dosing Regimen to Treat Patients with Irritable Bowel Disease
Indirect Homogeneous Mobility Shift Assays for the Detection of Biologics in Patient Samples
Pathway Specific Markers for Diagnosing Irritable Bowel Syndrome
Pathway Specific Assays for Predicting Irritable Bowel Syndrome Diagnosis
Application:
15/847,406 →
Publication:
US 2018/0136233
Pathway Specific Markers for Diagnosing Irritable Bowel Syndrome
Addressable Antibody Arrays and Methods of Use
Application:
16/036,180 →
Publication:
US 2018/0321254
Methods of Disease Activity Profiling for Personalized Therapy Management
Method of determining thiopurine methyltransferase activity
Application:
60/205,695 →
Methods of diagnosing tissue fibrosis
Application:
60/514,034 →
Methods for optimizing clinical responsiveness to chemotherapy
Application:
60/514,423 →
Methods for optimizing clinical responsiveness to low-dose anti-folate therapy
Application:
60/560,752 →
Inflammatory bowel disease assay system
Application:
60/571,216 →
Methods for predicting methotrexate polyglutamate levels using pharmacogenetics
Application:
60/580,141 →
Methods to optimize thiopurine therapy and reduce toxicity using metabolite profiling and mass spectrometry
Application:
60/628,728 →
Methods for evaluating risk associated with methotrexate therapy using pharmacogenetics
Application:
60/676,442 →
Methods for monitoring methotrexate therapy using pharmacogenomic and metabolite biomarkers
Application:
60/731,598 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
60/822,488 →
Crohn disease susceptibility gene
Application:
60/833,261 →
Crohn disease susceptibility gene
Application:
60/834,151 →
Methods of Diagnosing Irritable Bowel Syndrome
Application:
60/884,397 →
Methods of Diagnosing Intestinal Disorders
Application:
60/893,594 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
60/895,962 →
Genome-wide association scan identifites nell1 as a novel IBD disease gene and 5p13.1 as a female-specific susceptibility region for Crohn disease
Application:
60/907,543 →
Genome-wide association scan identifites NELL1 as a novel IBD disease gene and 5p13.1 as a female-specific susceptibility region for Crohn disease
Application:
60/919,953 →
Method and system for assisting in diagnosing irritable bowel syndrome
Application:
60/921,486 →
Methods of diagnosing inflammatory bowel disease
Application:
60/934,919 →
Publication:
US 2006/0154276
Addressable Antibody Arrays and Methods of Use
Application:
60/972,724 →
Methods to Predict Risk and Severity for Celiac Disease
Application:
61/031,636 →
Methods of Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
Application:
61/113,537 →
Methods of Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
Application:
61/118,346 →
Methods to Predict Risk and Severity for Celiac Disease
Application:
61/118,968 →
Citrullinated Peptides for Diagnosing and Prognosing Rheumatoid Arthritis
Application:
61/164,840 →
Methods of Inflammatory Bowel Disease Prognosis and Biological Response Prediction
Application:
61/169,230 →
Methods of Inflammatory Bowel Disease Prognosis and Biological Response Prediction
Application:
61/178,454 →
Methods to Predict Probability for Surgery in Crohn's Disease Patients
Application:
61/220,453 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
61/220,525 →
Diagnosis and Treatment of Early Onset Rheumatoid Arthritis
Application:
61/243,496 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
61/252,094 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/255,048 →
Diagnosis and Treatment of Early Onset Rheumatoid Arthritis
Application:
61/255,058 →
Methods to Predict Probability for Surgery in Crohn's Disease Patients
Application:
61/255,066 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
61/256,717 →
Methods for Predicting Post-Surgery Risk Associated with Ileal Pouch-Anal Anastomosis
Application:
61/259,978 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/262,877 →
Inflammatory Bowel Disease Prognostics
Application:
61/262,903 →
Methods of Diagnosing Irritable Bowel Syndrome
Application:
61/264,588 →
Novel Genomic Biomarkers for Irritable Bowel Syndrome Diagnosis
Application:
61/264,634 →
Inflammatory Bowel Disease Prognostics
Application:
61/265,324 →
Methods for Prediction of Inflammatory Bowel Disease (Ibd) Using Serologic Markers
Application:
61/265,723 →
Inflammatory Bowel Disease Prognostics
Application:
61/286,356 →
Inflammatory Bowel Disease Prognostics
Application:
61/300,787 →
Inflammatory Bowel Disease Prognostics
Application:
61/302,066 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/324,635 →
Methods for Diagnosing Irritable Bowel Syndrome
Application:
61/326,176 →
Methods for Predicting Post-Surgery Risk Associated with Ileal Pouch-Anal Anastomosis
Application:
61/334,348 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/345,567 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/351,269 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/351,837 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/354,141 →
Assays and Methods for the Detection of Crohn's Disease
Application:
61/367,328 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/389,672 →
Development of Assays for the Detection of Anti-Tnf Drugs and Autoantibodies
Application:
61/393,581 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/393,588 →
Methods for Optimizing Therapy with Anti-Tnf Drugs
Application:
61/394,269 →
HER2DELTA16 Peptides
Application:
61/419,210 →
Performance of a Biomarker Panel for Irritable Bowel Syndrome
Application:
61/486,734 →
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia and Cancer
Application:
61/497,016 →
Methods for Optimizing Therapy with Anti-Tnf Drugs
Application:
61/505,031 →
Compositions and Methods for Detecting Allelic Variants
Application:
61/525,137 →
Methods for Optimizing Therapy with Anti-Tnf Drugs
Application:
61/528,072 →
Methods for Optimizing Therapy with Anti-Tnf Drugs
Application:
61/535,884 →
Methods for Determining Combination Therapy with Proleukin for the Treatment of Cancer
Application:
61/537,502 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/550,293 →
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia and Cancer
Application:
61/551,330 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/553,853 →
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia and Cancer
Application:
61/565,445 →
Performance of a Biomarker for Irritable Bowel Syndrome
Application:
61/566,521 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/567,096 →
Methods for Improving Inflammatory Bowel Disease Diagnosis
Application:
61/570,271 →
Compositions and Methods for Detecting Allelic Variants
Application:
61/588,151 →
Assays for Measuring Anti-Tnf Drug and Anti-Drug Antibody Levels
Application:
61/622,484 →
Assays for Measuring Anti-Tnf Drug and Anti-Drug Antibody Levels
Application:
61/646,115 →
Methods for Identifying Inflammatory Bowel Disease Patients with Dysplasia and Cancer
Application:
61/648,529 →
MOBILITY SHIFT ASSAYS FOR DETECTING ANTI-TNFalpha DRUGS AND AUTOANTIBODIES THERETO
Application:
61/683,681 →
Assays for Measuring Anti-Tnf Drug and Anti-Drug Antibody Levels
Application:
61/700,855 →
Assays for Measuring Anti-Tnf Drug and Anti-Tnf Drug Antibody Levels
Application:
61/716,415 →
Assays for Measuring Anti-Tnf Drug and Anti-Drug Antibody Levels
Application:
61/717,592 →
Assays for Detecting Neutralizing Autoantibodies to Biologic Therapy
Application:
61/732,251 →
Multi-Protein Serum Test Predicts Mucosal Healing in Children with Ileocolonic Crohn's Disease
Application:
62/775,039 →
Related Assignments
(18)
Other recorded transfers of the patents in this record — the chain of ownership.
Short-Form Patent Security Agreement
Oct 15, 2013
From: EXAGEN DIAGNOSTICS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031414/0660 →
Release of Security Interest
Dec 29, 2015
From: BANK OF AMERICA, N.A.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 037378/0464 →
Release of Security Interest
Sep 1, 2017
From: CYPRESS BIOSCIENCE INC.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043747/0382 →
Release of Security Interest
Sep 7, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043784/0828 →
Security Interest
Sep 11, 2017
From: EXAGEN DIAGNOSTICS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 043548/0228 →
Merger
Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
Corrective Assignment to Correct the English Translation to Show the Full and Correct New Name in Section 51. Previously Recorded at Reel: 049391 Frame: 0756. Assignor(S) Hereby Confirms the Merger.
Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
Merger
Aug 8, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049997/0344 →
Change of Name
Oct 17, 2019
From: PRECISION IBD, INC.
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 050886/0942 →
Corrective Assignment to Correct the Patent Number 16062921 Previously Recorded on Reel 049391 Frame 0756. Assignor(S) Hereby Confirms the Patent Number Should Have Been 16062912.
Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
Corrective Assignment to Correct the Patent Number 16062921 Previously Recorded on Reel 049391 Frame 0756. Assignor(S) Hereby Confirms the Patent Number Should Have Been 16062912.
Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
Assignment of Assignor's Interest
Feb 8, 2021
From: PROMETHEUS BIOSCIENCES, INC.
To: PROMETHEUS LABORATORIES, INC.
Reel/Frame 055256/0976 →
Assignment of Assignor's Interest
Jun 21, 2021
From: PROMETHEUS BIOSCIENCES, INC.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 056635/0750 →
Assignment of Assignor's Interest
Sep 10, 2021
From: PROMETHEUS BIOSCIENCES, INC.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 057452/0129 →
Assignment of Assignor's Interest
Oct 7, 2021
From: PROMETHEUS BIOSCIENCES, INC.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 057730/0993 →
Assignment of Assignor's Interest
Nov 3, 2021
From: PROMETHEUS LABORATORIES INC.
To: EXAGEN INC.
Reel/Frame 058007/0978 →
Release of Security Interest
Apr 25, 2025
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: EXAGEN INC.
Reel/Frame 070951/0040 →
Security Interest
Apr 25, 2025
From: EXAGEN INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 070952/0802 →